Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma

Oncogene

Volumn 29, Issue 35, 2010, Pages 4938-4946

  Shang, X ^a   Vasudevan, S A ^a   Yu, Y ^a   Ge, N ^a   Ludwig, A D ^a   Wesson, C L ^a   Wang, K ^a   Burlingame, S M ^a   Zhao, Y J ^a   Rao, P H ^a   Lu, X ^b   Russell, H V ^a   Okcu, M F ^a   Hicks, M J ^a   Shohet, J M ^a   Donehower, L A ^a   Nuchtern, J G ^a   Yang, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

doxorubicin; DUSP26; MKP8; neuroblastoma; p53; phosphatase

Indexed keywords

DOXORUBICIN; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 26; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 8; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DUSP26 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; SERINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN IMR 32; CELL STRAIN SK N SH; CHEMOSENSITIVITY; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEUROBLASTOMA; PHOSPHORYLATION; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956341371     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.244     Document Type: Article

References (35)

1. Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R et al. (2009). Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol 92: 357-371.
2. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
3. Brooks CL, Gu W. (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
4. Chehnab NH, Malikazy A, Stravridi ES, Halazonetis TD. (1999). Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782.
5. Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C et al. (2007). p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 6: 2685-2696.
6. Eischen CM, Lozano G. (2009). p53 and MDM2: antagonists or and differentiated neuroblastoma. Cell Cycle 6: 2685-2696
7. Eischen CM, Lozano G. (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell 15: 161-162.
8. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807-1815.
9. Goldman SC, Chen CY, Lowsing TJ, Gilmer TM, Kastan MB. (1996). The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 148: 1381-1385.
10. Hupp TR, Lane DP, Ball KL. (2000). Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 352 (Part 1) 1-17.
11. Jeffrey KL, Camps M, Rommel C, Mackay CR. (2007). Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6: 391-403.
12. Kruse JP, Gu W. (2009). Modes of p53 regulation. Cell 137: 609-622.
13. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
14. Li DW, Liu JP, Schmid PC, Schlosser R, Feng H, Liu WB et al. (2006). Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 25: 3006-3022.
15. Li L, Ljungman M, Dixon JE. (2000). The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53. J Biol Chem 275: 2410-2414.
16. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H et al. (2005). Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Childrens Oncology Group. J Clin Oncol 23: 6459-6465.
17. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE et al. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
18. Lu X, Nannenga B, Donehower LA. (2005). PPM1D dephospho-rylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19: 1162-1174.
19. Maruta H, Holden J, Sizeland A, DAbaco G. (1991). The residues of Ras and Rap proteins that determine their GAP specificities. J Biol Chem 266: 11661-11668.
20. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB et al. (1998). Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Childrens Cancer Group study. J Clin Oncol 16: 1256-1264.
21. Moll UM, LaQuaglia M, Benard J, Riou G. (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411.
22. Patterson KI, Brummer T, OBrien PM, Daly RJ. (2009). Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418: 475-489.
23. Pestell KE, Ducruet AP, Wipf P, Lazo JS. (2000). Small molecule inhibitors of dual specificity protein phosphatases. Oncogene 19: 6607-6612.
24. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA et al. (2009). Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8: 2461-2469.
25. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A et al. (2005). The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 102: 731-736.
26. Toledo F, Wahl GM. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923.
27. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61: 8-13.
28. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C et al. (2003). The p53 pathway and its inactivation in neuroblas-toma. Cancer Lett 197: 93-98.
29. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G et al. (1999). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18: 1805-1814.
30. Vasudevan SA, Skoko J, Wang K, Burlingame SM, Patel PN, Lazo JS et al. (2005). MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem Biophys Res Commun 330: 511-518.
31. Vasudevan SA, Shang X, Chang S, Ge N, Diaz-Miron JL, Russel HV et al. (2009). Neuroblastoma derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. Mol Cancer Ther 8: 2478-2489.
32. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
33. Vousden KH, Lu X. (2002). Live or let die: the cells response to p53. Nat Rev Cancer 2: 594-604.
34. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. (2007). A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26: 1178-1187.
35. Yu Y, Ge N, Xie M, Sun W, Burlingame S, Pass AK et al. (2008). Phosphorylation of Thr-178 and Thr- 184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression. J Biol Chem 283: 24497-24505.